Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2020 09/22/2020 09/23/2020 09/24/2020 09/25/2020 Date
64.21(c) 63.4(c) 63.09(c) 62.25(c) 61.98 Last
8 575 185 7 228 235 8 520 245 9 004 618 2 296 203 Volume
-1.29% -1.26% -0.49% -1.33% -0.43% Change
More quotes
Financials (USD)
Sales 2020 24 281 M - -
Net income 2020 2 423 M - -
Net Debt 2020 3 137 M - -
P/E ratio 2020 34,0x
Yield 2020 4,33%
Sales 2021 24 050 M - -
Net income 2021 7 400 M - -
Net Debt 2021 1 353 M - -
P/E ratio 2021 10,2x
Yield 2021 4,61%
Capitalization 78 044 M 78 044 M -
EV / Sales 2020 3,34x
EV / Sales 2021 3,30x
Nbr of Employees 11 800
Free-Float 99,6%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GILEAD SCIENCES, INC.
02:01aGILEAD SCIENCES : Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthri..
BU
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
RE
09/24GLOBAL MARKETS LIVE : Ion Media, Costco Wholesale, Tesla…
09/24GILEAD SCIENCES : Prices $7.25 Billion of Senior Unsecured Notes
AQ
09/23GILEAD SCIENCES : Prices $7.25 Billion of Senior Unsecured Notes
BU
09/23Gilead to pay $97 million to settle U.S. kickback probe
RE
09/19IMMUNOMEDICS : drug Trodelvy extends survival in breast cancer patients
RE
09/17GILEAD SCIENCES : to acquire Immunomedics for $21 billion
AQ
09/16GILEAD SCIENCES : Magrolimab an Investigational Anti-CD47 Monoclonal Antibody, R..
AQ
09/15Tech, healthcare mega deals boost virus-stricken M&A market
RE
09/15GILEAD SCIENCES : Magrolimab Gets FDA Breakthrough Therapy Designation in Myelod..
DJ
09/15GILEAD SCIENCES : Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, ..
BU
09/15Tech leads crisis-driven M&A boom with $350 billion deal rush
RE
09/15Tech Stocks Lead Index Rebound -- WSJ
DJ
09/15Tech leads crisis-driven M&A boom with $350 billion deal rush
RE
More news
News in other languages on GILEAD SCIENCES, INC.
09/24Ça se tend à tous les étages
09/24EN DIRECT DES MARCHES : Airbus, Suez, Valeo, Trigano, Voltalia, Recylex, Ahlstro..
09/23GILEAD : amende de 97 millions USD pour des paiements illégaux aux patients
09/23Résultats cliniques positifs pour un médicament de Fujifilm
09/15USA: Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Stock Trading Strategies
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 78,79 $
Last Close Price 62,25 $
Spread / Highest target 68,7%
Spread / Average Target 26,6%
Spread / Lowest Target -0,40%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-4.20%78 044
VERTEX PHARMACEUTICALS20.18%68 537
REGENERON PHARMACEUTICALS48.47%58 662
WUXI APPTEC CO., LTD.47.17%34 473
BEIGENE, LTD.66.85%25 001
GENMAB A/S52.14%23 029